MVM Capital has raised its fourth and largest funding round. It now has an additional €204M to invest in healthcare in the US and Europe.
With offices in Boston and London, MVM Capital is an important VC in the healthcare sector – from biotechnology to medical devices.
Its biggest success story is perhaps Heptares, a UK Biotech researching applications of G protein-coupled receptors (GPCRs) that was acquired by Sosei (Japan) – and went on to make billion euro deals with Pfizer and Allergan.
MVM has now closed its fourth healthcare fund (MVM IV), raising a total of €204M ($233M). This is a record for MVM, which has so far raised over €600M in its four funds.
MVM intends to spend their new funds mainly in a medical companies from the US and Europe.
It will consider all stages of development, as well as a range of sectors – from new therapeutics to medical devices and healthcare bioinformatics. The estimated investment per company will be from around €13M ($15M) to €26M ($30M).
A fair share of the current MVM’s portfolio is based in Europe, with companies like Wilson Therapeutics (Sweden), which is tackling a rare genetic disorder, as well as UK Biotechs Pulmagen Therapeutics and Xention.